BEARINGPOINT
17.9.2020 08:57:22 CEST | Business Wire | Press release
Management and technology consultancy BearingPoint announced today that it has acquired Paris-based Steerio, an engagement platform (SaaS) that leverages smart analytics to push teamwork, feedback and decision-making into the digital age. With the acquisition, BearingPoint expands its portfolio of team and project management assets and enhances its People & Strategy offering that focuses on the people dimension of a company’s strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005793/en/
The acquisition is part of a bigger strategic move: the independent consulting firm has been investing for years in new and better ways of working. This includes innovative project and team management and collaboration solutions across business units, countries and teams for more innovation, agile-working, and remote and mobile working - an approach embedded in the firm’s Strategy 2025, which puts people in the center. To accelerate this ambition, BearingPoint also created and included data-driven digital assets and managed services in its portfolio.
Steerio joins BearingPoint’s portfolio of team and project management assets such as Active Manager and enhances its People & Strategy offering. BearingPoint said Steerio will be rolled out to all projects of a certain size and complexity and will form a substantial pillar of the way the firm delivers consulting projects.
“The new normal demands that we create and bring to life new ways of working and related offerings,” said Kiumars Hamidian, Managing Partner BearingPoint. “Putting people in the center is a major ambition driving our Strategy 2025, and the acquisition of Steerio fits well with our portfolio of offerings because Steerio is both people-centric and data-driven at the same time. The Steerio platform opens even more innovative ways to collaborate across teams and firms for the best possible outcomes for our clients.”
“Working and collaboration in the 'new normal' is more important than ever, and Steerio’s smart analytics create an augmented project experience for all our team members, which we especially need in these times of remote working,” adds Damien Palacci, Global Leader Consulting Portfolio at BearingPoint. “It is another tool for us to use and leverage for better teamwork, knowledge transfer, and more innovation. And it also empowers employees and helps them take ownership and be entrepreneurs.”
Steerio captures weak signals and uses “soft-data” analytics and best-practices and team feedback to identify roadblocks and adopt best-practices proactively to secure team effectiveness. It reduces project failure and delays and promotes transparency and trust. Every stakeholder has access to anonymized and objective team results.
“Becoming part of BearingPoint is a giant leap for us, as it significantly increases our ability to provide a wider array of services to our clients,” said Damien Guery, Co-Founder of Steerio. “We can now combine our expertise and assets and leverage them with BearingPoint's extensive industry network. We are going to be able to push teamwork and decision-making into the digital age.”
About Steerio
Paris-based Steerio was started to bring teamwork, feedback and decision-making to the digital age, combining years of practical experience, best-practice methodologies and knowledge in artificial intelligence. By leveraging new types of data and enabling decision makers to access the relevant insights at the right time, Steerio unlocks tremendous efficiency gains in team delivery and improves the collaboration experience while reducing the gap between strategy design and execution.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business critical services to its clients supporting their business success. The third unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
BearingPoint's clients include many of the world's leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005793/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
